It depends on what your goal is but 200mg of tissue will result in up to 25000 peptides, whereas 10% of this starting material will generate between 8000 and 10000 peptides.

It strongly depends on the physico-chemical properties of the peptide that you wish to see but as a rule of thumb Alithea would ask for 1 million cells as a minimum requirement

Alithea has shown copy numbers of ~6 per cell, but it strongly depends on the peptide characteristics. Some peptides are better detected by the MS than others or have a higher recovery during the laboratory procedure. Nonetheless, an initial optimisation step will be performed to evaluate whether the peptide of interest can be detected.

Alithea has developed its protocols to minimize the variation as much as possible. For example, isotopically labelled peptides used for quantitation are introduced early in the protocol to correct for laboratory variation and limits of quantitation (LOQ) are calculated. Nevertheless, there is always a small error margin in laboratory experiments.

For HLA class I pulldowns we use use the W6/32 antibody For HLA Class II puldown we use the HLA-DR antibody.

With the exception of glycosylations you could request for specific PTM analysis. Feel free to get in touch with us so that we can discuss the strategy tailored to your experiments

Yes, and we could also source tumour and healthy tissue samples for our customers.

You can do searches in HLA-Compass by peptide, protein (uniprot and gene name) and HLA expression

Yes, all of Alithea’s samples in the database are HLA typed. HLA-Compass contains 139 HLA types which is near to complete (~95%). Besides HLA type, our database has much more metadata such as…

Yes, we curate our own MS data and the external data. We have stringent quality control in terms of processing, manual curation and validation. We check the number of peptides, purity (8-12 mers) and the number of 8-12-mers expected to bind. Then criteria apply.

This information is available, although not directly in HLA-Compass but it can be tracked back

Around 10% of the data of HLA-Compass was discovered internally at this stage, and this percentage will increase in the coming years.

Explore exciting career opportunities and job openings at Alithea Bio by visiting our careers page on the website.

Alithea Bio specializes in HLA peptide quantification, T-cell-mediated immunotherapies, and other innovative biotechnological solutions.

Alithea Bio enhances cancer treatment by pioneering T-cell therapies and advancing HLA peptide technologies to create safer and more effective solutions.

HLA peptide quantification involves measuring the peptides presented by HLA molecules, which is critical for developing personalized immunotherapies.

Alithea Bio leads in T-cell therapy innovation, offering cutting-edge solutions backed by extensive research and expertise in the field.

Immunopeptidomics is the study of peptide antigens presented by HLA molecules, which is essential for developing precise cancer immunotherapies.

Alithea Bio leverages artificial intelligence to improve the accuracy of HLA peptide characterization and streamline the development of new therapies.

Mass spectrometry is used by Alithea Bio for the precise analysis of peptides, which aids in developing targeted and effective cancer treatments.

To explore collaboration opportunities, contact Alithea Bio through the website for partnerships in groundbreaking biotech research.

Stay updated on the latest innovations in cancer treatment and biotechnology by visiting Alithea Bio’s news and events page.